Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

Abstract Background Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the therapeutic benefit and allow studying new approaches for resistant pa...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Andrea Sacconi, Paola Muti, Claudio Pulito, Giulia Urbani, Matteo Allegretti, Raul Pellini, Nikolay Mehterov, Uri Ben-David, Sabrina Strano, Paolo Bossi, Giovanni Blandino
Formaat: Artikel
Taal:English
Gepubliceerd in: BMC 2023-11-01
Reeks:Molecular Cancer
Onderwerpen:
HNSCC
Immunotherapy
Immune checkpoint inhibitor
p53
PDL1
c-MYC
Online toegang:https://doi.org/10.1186/s12943-023-01905-9

Internet

https://doi.org/10.1186/s12943-023-01905-9

Gelijkaardige items